Global H1N1 (swine flu) Vaccination Market Overview:
Swine flu is a respiratory infection caused by H1N1 virus, also known as swine flu virus. These viruses also infect the respiratory system of pigs causing barking cough, decrease in appetite, nasal secretions, & listless behavior. Influenza viruses can also be transmitted to human beings. Swine flu viruses can encourage genetic changes or mutations so that these are easily transmissible among humans. In April 2009, swine flu outbreak was first detected in Mexico & was caused due to the H1N1 virus. Symptoms of swine flu infection in humans are similar to influenza infection, these include cough, nasal secretions, headache, fatigue, & fever. Some of the key players profiled in the study are Baxter International Inc (United States), Butantan Institute (Brazil), Changchun Institute of Biological Products (China), Crucell N.V. (Netherlands), Csl (Australia), Denka Seiken Co Ltd (Japan), Green Cross Corp (South Korea), Glaxosmithkline Plc (United States), Hualan Biological Engineering Inc (China), Inovio Biomedical Corp (United States), Kitasato Institute (Japan) and Medimmune (United States).
On the basis of geography, the market of H1N1 (swine flu) Vaccination has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
If we see Market by , the sub-segment i.e. will boost the H1N1 (swine flu) Vaccination market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.Market Drivers
- Favorable government initiatives
- H1N1 virus spreads very quickly and easily
Market Trend
- Large-Scale Investments Pose Entry Barriers for Smaller Players
Restraints
- Availability of substitute treatment
- Limited consumer segments
Opportunities
- Opportunity for emerging economies
- Inclination towards cell-based manufacturing
Challenges
- strong competition with low profit margins
- Side-effects and safety issues related to vaccine
On April 26, 2009, public health officials from the Centers for Disease Control (CDC) and the U.S. Secretary of Homeland Security held a press conference and declared a national public health emergency. The declaration came in response to identification of a new novel Influenza A (H1N1) “swine flu” virus (combination of swine, bird and human influenza viruses) that was making people sick and causing deaths in Mexico. By June 11, the World Health Organization (WHO) raised the global influenza pandemic alert to the highest Phase 6 level.U.S. Food and Drug Administration (FDA) has approved the use of one dose of vaccine against 2009 H1N1 influenza virus for persons 10 years of age & older. For children who are 6 months through 9 years of age, two doses of the vaccine are recommended. These two doses should be separated by 4 weeks.
The global H1N1 (swine flu) vaccination market is highly fragmented & the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
Target Audience:
Manufacturer, Raw material supplier, Channel partners, Industry Association, Downstream Vendors, Governments and investment communities, Research organizations and associations and End users (hospitals, clinics)
Major Objectives Focused through this Study
To define, describe, and forecast the Global H1N1 (swine flu) Vaccination market on the basis of product [] , application [], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the H1N1 (swine flu) Vaccination market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the H1N1 (swine flu) Vaccination industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Merck & Co (United States), Novartis (Switzerland), Novavax (United States) and Omninvest (Switzerland).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the H1N1 (swine flu) Vaccination market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.